The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells
The only currently available approach to early efficacy testing of tuberculosis (TB) vaccine candidates is in vivo preclinical challenge models. These typically include mice, guinea pigs and non-human primates (NHPs), which must be exposed to virulent M.tb in a ‘challenge’ experiment following vacci...
Auteurs principaux: | Tanner, R, Hoogkamer, E, Bitencourt, J, White, A, Boot, C, Sombroek, CC, Harris, SA, O'Shea, MK, Wright, D, Wittenberg, R, Sarfas, C, Satti, I, Verreck, FAW, Sharpe, SA, Fletcher, HA, McShane, H |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
F1000Research
2021
|
Documents similaires
-
A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates
par: Tanner, R, et autres
Publié: (2021) -
A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates
par: Rachel Tanner, et autres
Publié: (2021-01-01) -
A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development
par: Pepponi, I, et autres
Publié: (2017) -
The cross-species mycobacterial growth inhibition assay (MGIA) project 2010-2014
par: Brennan, M, et autres
Publié: (2017) -
Tools for assessing the protective efficacy of TB vaccines in humans: in vitro mycobacterial growth inhibition predicts outcome of in vivo mycobacterial infection
par: Tanner, R, et autres
Publié: (2020)